Jason Guillot, MD
Otolaryngology/Facial Plastic Surgery · Mandeville, LANPI 1912126723
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,000 of the $12,750 with a category attached, or 86.3%. Aerin Medical Inc. accounts for 86.8% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $11,240, more than ten times the $741 reported in 2019.
Across 88 payments — averaging $144.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerin Medical Inc.$11K
- Acclarent, Inc$293
- GSK$228
- Sanofi$169
- Arrinex, Inc.$160
- Optinose US, Inc.$139
- plus $695 from 15 others
What the payments were for
- Consulting fees$11,00086%
- Food & beverage$1,71613%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerin Medical Inc. | 7 | $11,067 |
| Acclarent, Inc | 16 | $293 |
| GSK | 14 | $228 |
| Sanofi | 10 | $169 |
| Arrinex, Inc. | 1 | $160 |
| Optinose US, Inc. | 8 | $139 |
| Intersect ENT, Inc. | 5 | $137 |
| AbbVie | 5 | $137 |
| Medtronic | 2 | $68 |
| Regeneron Healthcare Solutions, Inc. | 4 | $63 |
| Novartis | 3 | $44 |
| Stryker | 1 | $34 |
| Amgen | 1 | $34 |
| Integra Lifesciences Corporation | 2 | $30 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Phadia US Inc. | 2 | $28 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| Alk-abello, Inc | 1 | $18 |
| Kaleo, Inc. | 1 | $15 |
| Organogenesis Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVAER STYLUS$11,000
- CLARIFIX$160
How this compares
Too few otolaryngology/facial plastic surgery providers in Louisianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 13 | $46,970 |
| Azelastine Hcl | 174 | $4,591 |
| Fluticasone Propionate | 269 | $3,800 |
| Epinephrine | 13 | $2,173 |
| Ipratropium Bromide | 87 | $2,098 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 19 | $2,041 |
| Wixela InhubFluticasone Propion/Salmeterol | 24 | $1,842 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $1,770 |
| Fluocinolone Acetonide Oil | 39 | $1,522 |
| Mupirocin | 40 | $1,329 |
| Dexamethasone | 39 | $1,132 |
| Ofloxacin | 42 | $1,042 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 94 | $893 |
| Cephalexin | 96 | $678 |
| Methylprednisolone | 106 | $644 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAEpinephrine | $23 | $2,17313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few otolaryngology/facial plastic surgery providers in Louisianaon file to place this against a meaningful peer group, so we don't.
Other otolaryngology/facial plastic surgery in Mandeville
- Matthew MigneronNew Orleans$2K
- Robert ThorntonShreveport$1K
- Laura HetzlerBaton Rouge$1K
- Celeste GaryNew Orleans$1K
- Duncan HanbyLafayette$477
- Elisabeth RareshideNew Orleans$245
- Roxana BaratelliNew Orleans$86
- Tynes MixonNew Iberia$83
- Harold BienvenuNew Iberia$33
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.